Aytu BioPharma, Inc. (AYTU)
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutics and consumer healthcare products. The company's portfolio targets areas like ADHD, allergies, and insomnia, addressing unmet medical needs in the US and internationally.
Company Overview
Aytu BioPharma is a specialty pharmaceutical company targeting niche markets with established products like Adzenys XR-ODT and Tuzistra XR. With a focus on ADHD and other therapeutic areas, Aytu offers a diverse portfolio and aims to expand its commercial reach in the US and internationally, despite current profitability challenges.
Investment Thesis
Investing in Aytu BioPharma presents a speculative opportunity. While the company has a diverse product portfolio targeting specific therapeutic areas, its negative P/E ratio of -0.98 and a profit margin of -39.0% indicate significant profitability challenges. Growth catalysts include potential expansion of existing product lines and successful commercialization of new therapeutics. The company's low beta of 0.38 suggests lower volatility compared to the broader market. However, the investment thesis hinges on Aytu's ability to improve its financial performance and achieve profitability through strategic partnerships and effective marketing of its products.
Key Highlights
- Market capitalization of $0.02 billion reflects its small-cap status within the pharmaceutical industry.
- Gross margin of 66.0% indicates strong pricing power on its existing product portfolio.
- Negative P/E ratio of -0.98 highlights current unprofitability.
- Profit margin of -39.0% demonstrates the need for improved cost management and revenue generation.
- Beta of 0.38 suggests lower volatility compared to the overall market.
Competitors
Strengths
- Diverse portfolio of specialty pharmaceutical products.
- Established presence in the ADHD market.
- Existing distribution network and sales force.
- Proprietary formulations and brand recognition.
Weaknesses
- Negative profitability and high operating expenses.
- Reliance on a limited number of key products.
- Small market capitalization and limited financial resources.
- Intense competition in the specialty pharmaceutical industry.
Catalysts
- Ongoing: Potential for new product acquisitions or licensing agreements to expand the portfolio.
- Ongoing: Expansion of marketing and sales efforts to increase product awareness and market share.
- Ongoing: Positive clinical trial results for new formulations or indications.
- Ongoing: Strategic partnerships with other pharmaceutical companies or distributors.
Risks
- Potential: Failure to achieve profitability and manage operating expenses.
- Potential: Generic competition eroding market share of key products.
- Potential: Regulatory setbacks or delays in drug approvals.
- Ongoing: Dependence on key personnel and management team.
- Potential: Product liability claims or recalls.
Growth Opportunities
- Expansion of ADHD Product Line: Aytu can capitalize on the growing ADHD market by expanding the reach of Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys ER. The global ADHD market is projected to reach billions of dollars, offering significant growth potential. Aytu can focus on targeted marketing campaigns and strategic partnerships to increase market share and drive revenue growth within this therapeutic area. Timeline: Ongoing.
- Strategic Acquisitions and Licensing: Aytu can pursue strategic acquisitions and licensing agreements to expand its product portfolio and enter new therapeutic areas. By acquiring or licensing promising drug candidates, Aytu can diversify its revenue streams and reduce its reliance on existing products. This strategy can provide access to innovative therapies and accelerate growth. Timeline: Ongoing.
- International Expansion: Aytu has the opportunity to expand its commercial operations into international markets. By partnering with distributors or establishing a direct presence in key regions, Aytu can tap into new revenue streams and diversify its geographic footprint. International expansion can drive long-term growth and reduce reliance on the US market. Timeline: Ongoing.
- Development of Novel Formulations: Aytu can invest in the development of novel formulations and drug delivery systems to improve the efficacy and patient experience of its existing products. By creating innovative formulations, Aytu can differentiate its products from competitors and capture a larger share of the market. This strategy can enhance the value proposition of its portfolio and drive revenue growth. Timeline: Ongoing.
- Direct-to-Consumer Marketing: Aytu can leverage direct-to-consumer (DTC) marketing strategies to increase awareness and demand for its consumer healthcare products. By targeting consumers directly through online advertising and social media campaigns, Aytu can drive sales and build brand loyalty. DTC marketing can be a cost-effective way to reach a large audience and generate revenue. Timeline: Ongoing.
Opportunities
- Expansion into new therapeutic areas through acquisitions or licensing.
- International expansion to increase market reach.
- Development of novel formulations and drug delivery systems.
- Direct-to-consumer marketing to drive sales of consumer healthcare products.
Threats
- Generic competition and patent expirations.
- Regulatory hurdles and delays in drug approvals.
- Product liability claims and recalls.
- Economic downturns and changes in healthcare policies.
Competitive Advantages
- Proprietary formulations of existing drugs.
- Established brand recognition for certain products.
- Distribution network and relationships with pharmacies.
- Patent protection for some of its products.
About
Aytu BioPharma, Inc., established in 2015 and headquartered in Englewood, Colorado, is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapeutics and consumer healthcare products. Originally incorporated as Aytu BioScience, Inc., the company rebranded in March 2021 to reflect its evolving focus. Aytu's core business revolves around addressing unmet medical needs in the United States and internationally through a portfolio of prescription and consumer health products. Their key offerings include Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys ER, all indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in various age groups. Beyond ADHD, Aytu provides Karbinal ER for allergy relief, Poly-Vi-Flor and Tri-Vi-Flor supplements for pediatric fluoride deficiency, Tuzistra XR as an antitussive, and ZolpiMist for insomnia. Aytu aims to leverage its established product base and strategic partnerships to drive growth and expand its market presence within the specialty pharmaceutical landscape.
What They Do
- Develop and commercialize prescription drugs.
- Offer treatments for Attention Deficit Hyperactivity Disorder (ADHD).
- Provide medications for seasonal and perennial allergies.
- Distribute prescription supplements for infants and children.
- Offer prescription antitussives for cough relief.
- Market oral sprays for the treatment of insomnia.
Business Model
- Develops and acquires rights to pharmaceutical products.
- Manufactures or outsources the manufacturing of its products.
- Markets and sells products through its sales force and distribution network.
- Generates revenue through product sales to pharmacies and healthcare providers.
Industry Context
Aytu BioPharma operates within the specialty pharmaceutical industry, a sector characterized by its focus on niche markets and specialized treatments. The industry is driven by innovation, regulatory approvals, and the increasing demand for targeted therapies. Competition is intense, with companies vying for market share through product differentiation and strategic partnerships. Aytu's focus on ADHD and other specific therapeutic areas positions it within a growing segment of the pharmaceutical market, but it must navigate the challenges of regulatory hurdles and competitive pressures from larger, more established players.
Key Customers
- Patients with ADHD
- Individuals suffering from allergies
- Infants and children with fluoride deficiency
- Patients experiencing cough and cold symptoms
- Adults with insomnia
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $15M | -$11M | $0.00 |
| Q3 2025 | $14M | $2M | $0.00 |
| Q2 2025 | $15M | -$20M | $0.00 |
| Q1 2025 | $18M | $4M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Aytu BioPharma, Inc. (AYTU) stock price: $2.17 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- •Community sentiment has shifted positively, with discussions highlighting Aytu's innovative product pipeline and recent advancements in research.
- •Market perception has been bolstered by recent partnerships that enhance Aytu's reach and credibility in the pharmaceutical industry.
- •Recent news regarding regulatory approvals has sparked optimism among investors, suggesting that Aytu is on the right path to growth.
Why Bear
- •Despite recent positive sentiment, some investors remain cautious due to historical volatility in Aytu's stock performance.
- •Concerns about competition in the biotech space could overshadow Aytu's advancements, leading to skepticism about its market position.
- •Community discussions reflect a divide, with some members expressing doubts about the sustainability of Aytu's recent gains.
- •Ongoing challenges in securing funding for clinical trials may pose risks to Aytu's long-term growth prospects, causing hesitation among investors.
Latest News
-
Earnings Scheduled For February 3, 2026
Benzinga · Feb 3, 2026
-
Earnings Scheduled For February 3, 2026
benzinga · Feb 3, 2026
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Sep 23, 2025
Technical Analysis
Rationale
AI-generated technical analysis for AYTU including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Aytu BioPharma, Inc. (AYTU) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for AYTU.
Make a Prediction
Set your price target for Aytu BioPharma, Inc. (AYTU), choose a timeframe, and track your prediction accuracy.
Current price: $2.17
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AYTU.
Price Targets
Wall Street price target analysis for AYTU.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 2/100
Revenue declined -18.0% YoY, signaling shrinking demand or market headwinds.
-
Gross Margin 10/100
Gross margin of 66.8% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates AYTU's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Aytu BioPharma, Inc. do?
Aytu BioPharma is a specialty pharmaceutical company focused on developing and commercializing treatments for niche markets. Their portfolio includes prescription medications for ADHD, allergies, and insomnia, as well as consumer healthcare products. The company generates revenue through the sale of these products to pharmacies, healthcare providers, and consumers in the United States and internationally. Aytu aims to address unmet medical needs by providing targeted therapies and expanding its product offerings through strategic acquisitions and partnerships.
Is AYTU stock a good buy?
AYTU stock presents a high-risk, high-reward investment opportunity. The company's negative P/E ratio and profit margin highlight significant financial challenges. However, its diverse product portfolio and potential growth catalysts, such as strategic acquisitions and international expansion, could drive future value. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in AYTU, weighing the potential for significant gains against the risk of substantial losses. The stock's low beta may offer some downside protection during market volatility.
What are the main risks for AYTU?
Aytu BioPharma faces several key risks, including its current unprofitability and reliance on a limited number of key products. Generic competition could erode market share and pricing power. Regulatory setbacks or delays in drug approvals could negatively impact the pipeline. The company's small market capitalization and limited financial resources make it vulnerable to economic downturns and competitive pressures. Additionally, product liability claims or recalls could damage its reputation and financial performance.
Is AYTU a good stock to buy?
Whether AYTU is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the AYTU MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is AYTU data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for AYTU?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Aytu BioPharma, Inc..
Who are AYTU's main competitors?
Aytu BioPharma, Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how AYTU compares.
What do analysts say about AYTU?
Analyst ratings and price targets for AYTU are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is AYTU's market cap?
Market capitalization reflects the total market value of AYTU's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has AYTU stock performed recently?
Check the Chart & Info tab for AYTU's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in AYTU?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for AYTU-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling AYTU?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for AYTU.
Is AYTU a good stock for beginners?
Aytu BioPharma, Inc. (AYTU) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is AYTU for first-time investors?
Every stock carries risk, including Aytu BioPharma, Inc. (AYTU). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like AYTU.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update. Financial data is based on the most recent available information.